A Director at Blueprint Medicines is Exercising Options


Yesterday it was reported that a Director at Blueprint Medicines (BPMC), Charles Rowland, exercised options to sell 11,818 BPMC shares at $9.46 a share, for a total transaction value of $1.12M.

This is Rowland’s first transaction since reporting a Buy transaction on VKTX back in May 2018

See today’s analyst top recommended stocks >>

Currently, Blueprint Medicines has an average volume of 397.3K. The Company has a Price to Book ratio of 11.9112.

Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $114.25, reflecting a 23.1% upside.

Charles Rowland’s trades have generated a -54.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Blueprint Medicines Corp. is a precision therapy company, which focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy in October 2008 and is headquartered in Cambridge, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts